Objective: Our objective was to develop and validate a prognostic score for predicting mortality at the time of extracorporeal membrane oxygenation initiation for children with respiratory failure. Preextracorporeal membrane oxygenation mortality prediction is important for determining center-specific risk-adjusted outcomes and counseling families. Design: Multivariable logistic regression of a large international cohort of pediatric extracorporeal membrane oxygenation patients. Setting: Multi-institutional data. Patients: Prognostic score development: A total of 4,352 children more than 7 days to less than 18 years old, with an initial extracorporeal membrane oxygenation run for respiratory failure reported to the Extracorporeal Life Support Organization's data registry during 2001-2013 were used for derivation (70%) and validation (30%). Bidirectional stepwise logistic regression was used to identify factors associated with mortality. Retained variables were assigned a score based on the odds of mortality with higher scores indicating greater mortality. External validation was accomplished using 2,007 patients from the Pediatric Health Information System dataset. Interventions: None. Measurements and Main Results: The Pediatric Pulmonary Rescue with Extracorporeal Membrane Oxygenation Prediction score included mode of extracorporeal membrane oxygenation; preextracorporeal membrane oxygenation mechanical ventilation more than 14 days; preextracorporeal membrane oxygenation severity of hypoxia; primary pulmonary diagnostic categories including, asthma, aspiration, respiratory syncytial virus, sepsis-induced respiratory failure, pertussis, and "other"; and preextracorporeal membrane oxygenation comorbid conditions of cardiac arrest, cancer, renal and liver dysfunction. The area under the receiver operating characteristic curve for internal and external validation datasets were 0.69 (95% CI, 0.67-0.71) and 0.66 (95% CI, 0.63-0.69). Conclusions: Pediatric Pulmonary Rescue with Extracorporeal Membrane Oxygenation Prediction is a validated tool for predicting in-hospital mortality among children with respiratory failure receiving extracorporeal membrane oxygenation support. (Crit Care Med 2017; 45:e58-e66) Key Words: decision support; extracorporeal membrane oxygenation; pediatric; predictive score model; respiratory failure T he stated indications for extracorporeal membrane oxygenation (ECMO) candidacy include a "reversible condition with a high-predicted mortality rate if
conventional management is continued" (1) . However, lack of randomized control trials and prognostic prediction models complicates the ability to predict reversibility of the condition or mortality if ECMO is used.
Despite innovations in ECMO support, in-hospital mortality over the last decade for children more than 30 days old who receive ECMO for respiratory failure has remained stable at ~ 50% (2, 3) . Mortality is influenced by an increasing prevalence of comorbid conditions, in addition to the primary pulmonary diagnoses (2, 3) .
Recently, adult scoring systems have been developed using a variety of pre-ECMO factors, to help guide prognosis related to respiratory failure supported by ECMO (4, 5) . Pediatric scoring systems are not yet reported.
Our aim was to develop and validate a prognostic scoring tool to predict in-hospital mortality for children with respiratory failure who received ECMO by using pre-ECMO data available in the Extracorporeal Life Support Organization (ELSO) registry. The ELSO registry uses a standardized form to voluntarily collect ECMO patient data from over 449 international centers. The Pediatric Pulmonary Rescue with ECMO Prediction (P-PREP) score we developed is beneficial for purposes of risk adjusting for severity of illness when determining center-specific outcomes and family counseling.
METHODS
With approval from the ECMO Registry Committee of ELSO, we analyzed the deidentified data for all children more than 7 days to less than 18 years old who required ECMO primarily for respiratory failure from 2001 to 2013 (http://www.elso.org, accessed May 2014). Our primary outcome was in-hospital mortality after ECMO. We excluded neonates from our study defined as less than 14 days for data from 2001 to 2007. We excluded infants less than 7 days old for data collected from 2008 to 2013 given a recent report demonstrating that pediatric and neonatal outcomes do not differ after 7 days of life (6) . Only those with an International Classification of Diseases, 9th Edition (ICD-9) diagnostic code that indicated a primary pulmonary diagnosis were included. Analysis was restricted to the first ECMO run and included demographic data, year of ECMO run, mode of ECMO, pre-ECMO variables, ICD-9 diagnostic codes, procedure and complication codes, and hospital outcome. ECMO mode was categorized as venoarterial for any mode using an arterial cannula and venovenous for any mode without an arterial cannula. Pre-ECMO variables included pre-ECMO cardiac arrest, pre-ECMO therapies (high frequency ventilation, use of inhaled nitric oxide, ventilator settings, neuromuscular blockers, and Fio 2 ), and blood gases.
Prediction Variables
Predictors of mortality were limited to variables in the ELSO dataset and were selected by clinical reasoning and published reports (2, (7) (8) (9) (10) . Severity of hypoxia was categorized using the Pao 2 /Fio 2 ratio just prior to ECMO initiation (mild, 201-300 mm Hg; moderate, 101-200 mm Hg; and severe, ≤ 100 mm Hg) (11) . Initial blood pH prior to ECMO was categorized using the middle quartiles compared to the lowest and highest quartile and categorized. "Low quartile" was less than 7.11, "middle quartiles" was 7.11-7.34, and "high quartile" was greater than 7.34. The primary pulmonary diagnostic categories were independently assigned by the authors (S.B., L.Z., D.B.) according to the ICD-9 codes with disagreements resolved by consensus (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/C98). When more than one relevant ICD-9 code existed for the primary pulmonary diagnosis, we used the first relevant code recorded in the ELSO registry. Sepsis-induced respiratory failure was restricted to children whose primary diagnostic code was sepsis without additional pulmonary infections.
Because timing of injuries (with the exception of cardiac arrest) is not recorded in the ELSO registry, we assumed that all comorbid conditions occurred prior to ECMO, including renal and liver dysfunction. Bleeding and thrombotic events were excluded given the known propensity for these conditions to occur after ECMO initiation (12) . Hematopoietic stem cell transplant patients were excluded due to small sample size (n = 10, nine died), known high mortality odds, and concerns for over-fitting the multivariable model (2, 10) .
Statistical Analysis
Tool development and analysis utilized SAS 9.4 (SAS Institute, Cary, NC). The modeling dataset consisting of 4,352 ECMO runs was randomly divided into a development set (70%) and a validation set (30%), stratified by year. We used a complete-case analysis approach and only considered variables missing less than 10% of measurements. The development set was used for all variable selection and model building, and the validation set was retained to validate the final model. Candidate predictors of mortality were assessed with univariate logistic regression. Variables associated with mortality (p < 0.1) were included in the multivariate model building. The multivariate logistic regression model was built using a bidirectional stepwise selection process in which variables were added or removed from the model at each step based on the p value from the residual chi-square score statistic of less than or equal to 0.05. No variables were forced into the model.
The P-PREP tool was created using the estimated log-odds of mortality for patients supported with ECMO for respiratory failure. The log of the odds ratio for each variable was scaled and rounded to provide a simple integer value.
External Validation
External validation was performed using the Pediatric Health Information System (PHIS), which includes data from more than 40 children's hospitals. We queried for ECMO encounters using ICD-9 and charge codes from 2004 through the second quarter of 2014 (Supplemental Table 2 , Supplemental Digital Content 2, http://links.lww.com/CCM/C99). Patient inclusion required coding for both ECMO management and cannulation at age more than 7 days old and an ICD-9 code for respiratory failure (13) . We excluded all cases with ICD-9 or charge codes for cardiac surgery, cardiac transplant, cystic fibrosis, or mechanical support with a ventricular assist device. PHIS diagnosis and procedure classification used the same codes and rules as the ELSO data classifications. External validation was not performed using ECMO mode and severity of hypoxia, because these variables are not collected in PHIS. Duration of mechanical ventilation is also not collected, so we used the admission date as a proxy for ventilation start date given that all patients were admitted for respiratory failure.
RESULTS
A total of 4,621 ECMO runs for pediatric respiratory failure were reported to ELSO of which 4,498 (97.3%) represented first runs between 2001 and 2013. We analyzed 4,352 patients (96.7% of first runs) after excluding 146 for missing data. The following variables (% missing) were excluded from the model due to missing greater than 10% of measurements: peak endexpiratory pressure (53%), mean airway pressure (29%), peak inspiratory pressure (18%), and ventilatory rate (14%). The rates of missing measurements for variables included in the model were as follows: Fio 2 (7%), ventilation duration (6%), Paco 2 and Pao 2 (5%), and sex (1%). Less than 1% of all other variables were missing. The distribution of ELSO patients across the development and validation datasets are shown in Supplemental Table 3 (Supplemental Digital Content 3, http:// links.lww.com/CCM/C100).
Characteristics of ECMO survivors and nonsurvivors among ELSO registry patients are shown in Table 1 . Overall mortality was 43% and did not differ by sex. Later year of ECMO was associated with decreased mortality (p = 0.02), and 43% of all runs occurred from 2010 to 2013. The frequency of ECMO mode did not change over time and mortality with venovenous ECMO was lower compared to venoarterial ECMO (p < 0.01). Median overall duration of ECMO support was 7.9 days (interquartile range, 4.2-14.3 d). Median duration of mechanical ventilation prior to ECMO was 6.0 days, and overall 8% were ventilated more than 14 days, which was significantly associated with increased mortality (p < 0.001). Mortality risk increased with increasing severity of hypoxia (p ≤ 0.001), with severe hypoxia representing 88% of patients. Lower pH increased mortality (p < 0.001). The most common primary pulmonary diagnostic category was "other" (67%) followed by sepsis-induced respiratory failure (13%). Comparing across pulmonary diagnosis, death was more frequent in those with sepsis-induced respiratory failure and pertussis. The rates of coexisting comorbid conditions with each primary pulmonary diagnostic category are shown in Supplemental Table 4 (Supplemental Digital Content 4, http://links.lww.com/CCM/C101). Risk factors associated with mortality at the time of ECMO initiation by univariate analysis were age more than 10 years old, year of ECMO, venoarterial ECMO, mechanical ventilation more than 14 days, neuromuscular blockade, lower Pao 2 /Fio 2 ratio, lower pH, sepsis-induced acute respiratory distress syndrome (ARDS), pertussis, immunodeficiency, myocarditis, cardiac arrest, cancer, acute renal failure, and acute liver necrosis ( Table 2) . Asthma, aspiration, and respiratory syncytial virus were protective against mortality.
After final multiple logistic regression analysis, the P-PREP score retained mode of ECMO, mechanical ventilation more than 14 days, Pao 2 /Fio 2 ratio, pH, primary pulmonary diagnosis group, pre-ECMO cardiac arrest, cancer, acute renal failure, and acute liver necrosis and year of ECMO ( Table 3) . Year of ECMO use was not assigned a score, because the tool is intended to assist with clinical decisions at the time of ECMO initiation. A full description of the P-PREP score is shown in Table 3 and an online calculator is available at http://www.picuscientist.org/pprep. The prediction equation is exp(score/8.358 -1.2769)/(1+ exp[score/8.358 -1.2769]). Individual predicted in-hospital ECMO mortality risk is calculated by applying the P-PREP score to Figure 1 , which displays the 95% CI for mortality of the development dataset used to derive the score.
Higher scores are associated with greater predicted mortality. P-PREP scores between -1 and +20 represented 95% of all patients and 45% of patients scored between +3 and +8. All patients with score of less than or equal to -10 survived (n = 15), and all patients with scores more than 42 died (n = 2). Figure 2 displays the distribution of primary pulmonary diagnoses and comorbid conditions across the P-PREP scores. The areas under the receiver-operating characteristic curves (AUROC) in the development and internal validation sets were reasonable at 0. The model was externally validated using a PHIS dataset consisting of 2,007 patients with respiratory failure treated with ECMO and included a similar distribution of primary pulmonary diagnoses compared to data obtained from the ELSO registry with the exception of a larger proportion of primary sepsis-induced respiratory failure (26% vs 11%) and acute renal failure (38% vs 19%) (Supplemental Table 1 
DISCUSSION
We report on a prognostic tool to predict in-hospital mortality when ECMO is used for respiratory failure in pediatric patients. The tool was developed and validated using 4,352 patients in the ELSO registry over a 12-year period and externally validated using the PHIS administrative database. Our tool provides a real time prognostication of ECMO mortality to compare against the risks of the current therapies, including the risk of transporting to an ECMO center (14, 15) .
Mortality among pediatric patients with acute respiratory failure is significantly higher when there are two or more extrapulmonary organ system failures compared to one or none (2, (14) (15) (16) (17) (18) (19) (20) . Thus, the decision to transition to ECMO is difficult when comorbid conditions exist, because the risk of death with conventional therapies may appear similar to the risk of death if ECMO is used. Often, the transition to ECMO occurs only after a protracted treatment course or a sentinel event. We found that 8% of ELSO patients received mechanical ventilation for more than 14 days, and more than 15% had a cardiac arrest. Pre-ECMO assessment of mortality allows for risk stratification, which is increasingly important as we attempt to deal with the technical, ethical, and administrative issues inherent to high-risk, high-cost rescue therapies such as ECMO. An assessment of risk of mortality can also help risk-adjust for severity of illness when determining centerspecific outcomes, patient selection in clinical trials, and guiding conversations related to ECMO training and maintenance requirements.
Family counseling relative to clinical outcomes is currently limited by lack of trials and prognostic tools. The P-PREP score incorporates a variety of pre-ECMO clinical characteristics known to influence mortality into a single prognostic score that is unique to each patient. As therapies are deployed and the clinical condition evolves, the score can be recalculated to recalibrate the family and caregivers to the current risk of in-hospital mortality for pediatric respiratory failure, should ECMO be used.
Prior Prediction Models
The most recent adult predictive tool; the Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score, also used the ELSO registry and was developed using 2,355 adults over 13 years with acute respiratory failure (12) . Acute nonpulmonary-associated infections and CNS dysfunction were strongly associated with mortality and heavily influenced the RESP score. The RESP tool was validated using the PRedicting dEath for SEvere ARDS on VV-ECMO dataset consisting of 140 patients from three French ICUs diagnosed exclusively with ARDS, and achieved an AUROC of 0.74 (95% CI, 0.72-0.76) (4, 12) . Only duration of mechanical ventilation and pre-ECMO cardiac arrest were common to both the RESP and P-PREP tools.
Patients with a P-PREP score between 5 and 15, and RESP patients in category III, represent ~ 50% of both cohorts and have an estimated risk of mortality between 40% and 60%, which closely approximates overall mortality, thereby reducing discrimination in both tools.
The RESP study utilized enrollment and validation methods that enhanced its discrimination compared to the P-PREP tool. The RESP study excluded over 30% of patients for missing data compared with exclusion of only 5% of patients in our study which resulted in a larger proportion of our patients falling into the primary pulmonary diagnostic category "other" (67% in our cohort = "other" compared to ~ 30% in the RESP Critical Care Medicine www.ccmjournal.org e65 cohort). Analysis of the P-PREP tool after exclusion of the category "other" increases the AUROC to 0.74 (95% CI, 0.69-0.79) nearly matching the performance of the RESP score. The performance of the RESP tool is further enhanced by a validation cohort, which is small (represented only ~ 5% of the development cohort) and discrete (contained only patients with ARDS compared to the development cohort which included multiple types of "acute respiratory failure").
Limitations
Limitations include those inherent to the use of a retrospective registry-based analysis. Specifically, the influence of ECMO center characteristics, physiologic data, specific timing of injuries, interventions, morbidities, and functional status of survivors is not incorporated into the tool. Center infrastructure characteristics are likely to affect patient outcomes particularly for the highest risk patients who often require timely initiation of advanced treatments such as dialysis and bronchoscopy (6, 13, (21) (22) (23) . Although timing of injuries is not reported to ELSO, Gupta et al (24) found that renal function commonly improved after ECMO initiation suggesting most acute kidney injury occurs prior to ECMO.
Misclassification bias may have been introduced because many ICD-9 related conditions lack explicit definitions. We analyzed "acute renal failure" first using ICD-9 codes and second using creatinine greater than 1.5 mg/dL (which is also reported in the ELSO registry), and found no change in the tool's performance. Some children had multiple primary pulmonary diagnostic codes making it difficult to be certain that the first code in sequence truly represented the primary etiology for respiratory failure. Our tool prognosticates for mode of ECMO at the time of cannulation; however, our model assumed venoarterial for any patient with an arterial cannula at any point in time. ICD-9 coding also lacks illness severity scaling and activity which may be particularly important for patients with immune dysfunction which was not included in our model.
Our external validation was limited to variables in the PHIS database thereby excluding mode of ECMO and severity of hypoxia from analysis. Furthermore, duration of mechanical ventilation may be overestimated since patients could have been intubated at any time since admission. Given that all PHIS hospitals except two have submitted data to ELSO within the last 5 years, it is likely that there is patient overlap between the two registries. Also, the eras of comparison between ELSO (2001-2013) and PHIS (2004-2014) did not entirely overlap.
Finally, we lack a comparison database of non-ECMO patients with similar illnesses and thus our findings are applicable only to pediatric patients with respiratory failure for whom ECMO is chosen as a therapy and are not applicable to patients who do not receive ECMO.
CONCLUSIONS
The P-PREP tool is a validated tool to predict in-hospital mortality for children who receive ECMO for respiratory failure. It demonstrates that comorbid conditions strongly influence overall mortality regardless of primary pulmonary diagnosis. We anticipate it will be most useful for risk stratification and family counseling.
